Compare Ascendis Pharma A/S (ASND) vs CSX Corporation (CSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs CSX Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while CSX Corporation trades at $49.83 (market cap $91.81B). The key difference: CSX Corporation is far larger — about 5.2× Ascendis Pharma A/S's market cap, and CSX Corporation pays a 1.13% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CSX | |
|---|---|---|
Market Cap | $17.74B | $91.81B |
Sector | Health | Industrials |
52-Week High | $277.18 | $49.41 |
52-Week Low | $163.32 | $32.05 |
Enterprise Value | $18.11B | $110.04B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CSX trades at $49.41, slightly above the consensus price target of $48.21, with a 0.12% daily gain. The technical outlook is bullish based on moving averages, though RSI levels suggest overbought conditions. Recent earnings have shown mixed results, beating estimates in Q1 2026 but missing in Q4 2025, while revenue has declined from $14.9B in 2022 to $14.1B in 2025. The company maintains strong profitability with a 21.55% net income margin and recently announced a $0.14 dividend payable in June 2026.
The stock faces headwinds from declining revenue and high valuation multiples (P/E of 30.31), but analyst sentiment remains positive with 56.52% buy ratings. Key risks include freight demand volatility and elevated debt levels. Upside potential exists if operational improvements and margin expansion initiatives succeed, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
